JNJ-64140284

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium

Conditions

Healthy

Phase 1

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

TerminatedNCT03693391

Janssen Research & Development, LLCHealthy

Start: 2018-10-17End: 2019-03-13Updated: 2025-04-27

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

TerminatedNCT04033458

Janssen Research & Development, LLCHealthy

Start: 2019-07-29End: 2019-08-01Updated: 2025-04-27

A Study of JNJ-64140284 in Healthy Male Participants

TerminatedNCT04566926

Janssen Pharmaceutica N.V., BelgiumHealthy

Start: 2020-09-29End: 2021-04-05Updated: 2025-04-27